BioAtla
BCAB
79 hedge funds and large institutions have $71.3M invested in BioAtla in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 27 reducing their positions, and 17 closing their positions.
750% more call options, than puts
Call options by funds: $119K | Put options by funds: $14K
39% more capital invested
Capital invested by funds: $51.3M → $71.3M (+$19.9M)
0.05% less ownership
Funds ownership: 1.26% → 1.21% (-0.05%)
4% less funds holding
Funds holding: 82 → 79 (-3)
11% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 27
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.86M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.47M |
| 3 |
Renaissance Technologies
New York
|
+$628K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
+$312K |
| 5 |
Millennium Management
New York
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.17M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.07M |
| 3 |
O
OrbiMed
New York
|
-$1.72M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$908K |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$840K |
BCAB Hedge Fund Activity: Q4 2023 in Review
79 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q4 2023, worth a combined $71.3M — up 39% from $51.3M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BCAB and 14 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 24 added.
The largest buyer was Morgan Stanley, adding an estimated $3.86M. The largest seller was Tang Capital Management, cutting an estimated $2.17M.
- 79 institutional investors held BioAtla (BCAB) as of Q4 2023, down from 82 in Q3 2023.
- Funds reported $71.3M of BioAtla stock for Q4 2023, up 39% quarter-over-quarter.
- 14 funds opened new BioAtla positions in Q4 2023 and 17 closed out, a net change of -3 holders.
- The largest BioAtla buyer in Q4 2023 was Morgan Stanley, an estimated $3.86M added.
- The largest BioAtla seller in Q4 2023 was Tang Capital Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2023.